BidaskClub cut shares of GTX (NASDAQ:GTXI) from a strong-buy rating to a buy rating in a research note released on Wednesday.
GTXI has been the topic of a number of other research reports. Robert W. Baird restated a buy rating and set a $30.00 target price on shares of GTX in a report on Thursday, March 15th. ValuEngine upgraded GTX from a sell rating to a hold rating in a report on Wednesday, February 7th. Zacks Investment Research cut GTX from a hold rating to a sell rating in a report on Wednesday, January 10th. Finally, Stifel Nicolaus raised their target price on GTX from $16.00 to $45.00 and gave the stock a buy rating in a report on Monday, March 5th. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The company currently has a consensus rating of Buy and a consensus target price of $37.50.
GTXI stock opened at $19.37 on Wednesday. GTX has a 1-year low of $2.73 and a 1-year high of $23.40.
In other GTX news, insider Jason T. Shackelford sold 3,090 shares of the firm’s stock in a transaction dated Friday, January 5th. The stock was sold at an average price of $11.33, for a total transaction of $35,009.70. Following the transaction, the insider now owns 31,111 shares in the company, valued at $352,487.63. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, VP Henry Patton Doggrell sold 4,965 shares of the firm’s stock in a transaction dated Friday, January 5th. The stock was sold at an average price of $11.33, for a total value of $56,253.45. Following the transaction, the vice president now owns 54,804 shares in the company, valued at approximately $620,929.32. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 15,364 shares of company stock worth $174,074. Company insiders own 41.20% of the company’s stock.
A number of institutional investors and hedge funds have recently modified their holdings of GTXI. Abingworth LLP acquired a new stake in shares of GTX during the third quarter worth about $2,781,000. Caxton Corp acquired a new stake in shares of GTX during the third quarter worth about $531,000. Millennium Management LLC acquired a new stake in shares of GTX during the fourth quarter worth about $749,000. Finally, EAM Investors LLC acquired a new stake in shares of GTX during the fourth quarter worth about $551,000. Hedge funds and other institutional investors own 12.71% of the company’s stock.
GTx, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecules for the treatment of breast and prostate cancer, and other medical conditions. It focuses on the development of selective androgen receptor modulators (SARMs) for the treatment of breast cancer, stress urinary incontinence (SUI), and Duchenne muscular dystrophy (DMD); and selective androgen receptor degraders (SARDs) to treat progressive castration-resistant prostate cancer (CRPC).
Receive News & Ratings for GTX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GTX and related companies with MarketBeat.com's FREE daily email newsletter.